Which Programs to Keep Backing
A specialty‑focused company was evaluating several external portfolios to support therapy area expansion and needed to decide whether a two‑asset phase II bundle deserved a place in its foundational pipeline. One asset targeted a single patient population; the other spanned three, with uneven clinical data and a partially developed commercial story. Existing materials included TPP feedback and basic forecasts, but key commercial assumptions were lightly tested and not fully articulated, making it hard to judge how solid the portfolio’s case really was.
The work focused specifically on this two‑asset package within a broader, multi‑portfolio selection effort and had to be completed in under a month for a CEO‑level, board‑facing decision. With full access to the data room but no scope for fresh commercial work, the assessment relied on existing materials supported by therapy area experience, and pattern recognition built across prior BD commercial evaluations.
A structured review tool captured asset‑level observations in real time, including Pros, Cautions, Gaps, Key Questions, and Recommendation Notes, while tracking documents reviewed. Facts and assumptions were processed together through commercial judgment and therapy area knowledge, highlighting where the rationale was robust, where it leaned on optimistic or untested assumptions, and where uncertainties were left unaddressed. The board presentation was organized around the most decision‑relevant themes: opportunity, reimbursement, TPP responses, competitive dynamics, cross‑cutting risks, knowledge gaps, and a consolidated recommendation view.
The company shifted from viewing the portfolio as a generally attractive phase II package to a more nuanced picture of its strengths and vulnerabilities. One asset sat in a space with unserved unmet need; the other faced established products and a busy pipeline in a market with meaningful unmet need remaining, requiring a more defined role and indication‑sequencing plan. The review showed how TPP feedback was conditioned by competitive realities and exposed thin downside and sensitivity testing in the forecasts, including limited exploration of adverse event scenarios. Recommendations focused on the relative strength of the rationale within the portfolio and where gaps could most plausibly erode its case if left unaddressed.
The immediate outcome was a board‑ready assessment that brought commercial and competitive realism into focus using only existing data room materials, clarifying whether this specific portfolio still warranted ongoing investment. Findings were presented directly to the board, with discussion on reimbursement, competition, customer TPP reactions, and the implications of limited downside testing.
This is the kind of NPP work that reflects my approach: make assumptions explicit and bring structure to uncertainty so commercial recommendations are stronger without overreaching the evidence.